Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease

• Status: Unknown status
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find if Etanercept can improve the outcome of ocular lesions of Behcet's Disease treated with Methotrexate and Prednisolone

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept; Methotrexate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Behcet's Disease according to the International Criteria for Behcet's disease (ICBD)

• Active posterior uveitis and/or retinal vasculitis

Exclusion Criteria:

• Visual acuity inferior to 1/10 on Snellen chart

• Being under cytotoxic drugs or having received them in the past 2 months

• Not being able to follow the one year treatment and the regular follow ups